Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECHO Study
NCT02550067Completed
- Sponsor
- FHI 360
- Start
- Dec 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Randomised, open-label trial of medroxyprogesterone acetate, avatrombopag and copper intrauterine device in contraception (3 arms), sponsored by FHI 360. Primary endpoint: Risk of HIV acquisition at 18 months. Started Dec 2015; status: completed.
02
Drugs
medroxyprogesterone acetateavatrombopagcopper intrauterine device
03
Conditions
contraception
Beyond the preview
Go deeper on NCT02550067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550067.